05-Feb-25 |
Buy |
Nicolas Loebel |
12.60p | 25,000 |
£3,150.00 |
03-Feb-25 |
Buy |
Carolyn Cross |
12.50p | 149,225 |
£18,653.13 |
31-Jan-25 |
Buy |
Carolyn Cross |
12.50p | 100,000 |
£12,500.00 |
30-Jan-25 |
Buy |
Carolyn Cross |
12.00p | 200,775 |
£24,093.00 |
30-Jan-25 |
Buy |
Carolyn Cross |
12.00p | 200,775 |
£24,093.00 |
03-Feb-25 |
Buy |
Carolyn Cross |
12.50p | 149,225 |
£18,653.13 |
31-Jan-25 |
Buy |
Carolyn Cross |
12.50p | 100,000 |
£12,500.00 |
05-Feb-25 |
Buy |
Nicolas Loebel |
12.60p | 25,000 |
£3,150.00 |
Carolyn Cross |
156,314,029 |
£22,665,534 |
Nicolas Loebel |
3,538,991 |
£513,154 |
Junaid Bajwa |
1,193,697 |
£173,086 |
Jean Duvall |
1,163,529 |
£168,712 |
Jean Charest |
353,356 |
£51,237 |
Simon Sinclair |
256,327 |
£37,167 |
Carolyn Cross |
118,091,377 |
£17,123,250 |
M&G Plc |
40,588,235 |
£5,885,294 |
Robert Cross |
25,858,400 |
£3,749,468 |
Albemarle Life Sciences Fund |
15,105,882 |
£2,190,353 |
CRUX Asset Management |
9,298,090 |
£1,348,223 |
Chelverton Asset Management |
7,957,311 |
£1,153,810 |
14:31 |
907 @ 14.28p |
13:28 |
6,738 @ 14.84p |
11:28 |
40 @ 15.00p |
10:29 |
3,569 @ 14.85p |
09:30 |
20,000 @ 14.25p |
Chair |
Jean Charest |
CEO |
Carolyn Cross |
Top of Page
You are here:
research